文献速递其他结缔组织病

JAK抑制剂治疗检查点抑制剂相关免疫不良事件的治疗潜力:文献综述

The therapeutic potential for JAK inhibitors for immune-related adverse events from checkpoint inhibitors: a review of the literature.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

本文通过检索PubMed、EMBASE和MEDLINE截至2025年5月25日的病例报告/系列,描述JAK抑制剂用于检查点抑制剂所致免疫介导不良事件的作用。共纳入104例患者,多数接受托法替尼(82%),主要适应证为心肌炎(70%)、肌炎(33%)和肝炎(24%);38%患者观察到肿瘤进展,4%因肿瘤进展死亡。作者认为JAK抑制剂是治疗检查点抑制剂相关毒性的有前景选择,尤其在其它细胞因子抑制策略失败的患者中。

要点

  • 纳入104例患者,多数使用托法替尼(82%),最常见适应证为心肌炎(70%)。
  • 38%患者观察到肿瘤进展,4%因肿瘤进展死亡。
  • 作者认为JAK抑制剂对其它细胞因子抑制策略失败的患者可能有效。

核心结论

  • JAK抑制剂正成为治疗免疫检查点抑制剂相关毒性的有前景选择。
  • 目前已发表的证据主要来自病例报告和病例系列,提示其有效,尤其在其它细胞因子抑制策略失败的患者中。

研究设计与样本

  • 本文为文献综述,检索PubMed、EMBASE和MEDLINE从建库至2025年5月25日的病例报告/系列。
  • 纳入五种EMA许可的JAK抑制剂(托法替尼、巴瑞替尼、乌帕替尼、非戈替尼和鲁索替尼)以及培非替尼。
  • 纳入11种FDA批准的检查点抑制剂。
  • 纳入已发表的病例报告、病例系列和队列数据,共104例患者。

主要发现

  • 多数患者接受托法替尼(82%)。
  • 帕博利珠单抗单药是最常见的免疫检查点抑制剂。
  • 最常见肿瘤为肺癌(20%),其次为胃癌(17%)和转移性黑色素瘤(16%)。
  • JAK抑制剂治疗irAE的适应证主要为心肌炎(70%),其次为肌炎(33%)和肝炎(24%)。
  • 38%患者观察到肿瘤进展,14%保持缓解,4%患者因肿瘤进展死亡。

局限性

  • 目前已发表的证据主要来自病例报告和病例系列。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The role of JAK inhibitors in immune-mediated adverse events was not included in the EULAR 2021 guidance on the management of rheumatic immune-related adverse events (irAE) from checkpoint inhibitors or the society of immunotherapy of cancer guidelines on this topic. We aim to describe the role of JAK inhibitors for the management of immune-mediated adverse events with a review of case reports. METHODS: Pubmed, EMBASE and MEDLINE searches were performed from inception until 25 May 2025 for case reports/series of the use of JAK inhibitors to treat checkpoint inhibitor-induced immune adverse events. Five EMA-licensed JAK inhibitors (tofacitinib, baritinib, upadacitinib, filgotinib and ruxolitinib) were included in addition to peficitinib. The 11 FDA-approved checkpoint inhibitors were included. RESULTS: Published case reports, case series and cohort data included 104 patients. Most patients received tofacitinib (82%). Pembrolizumab monotherapy represented the most common immune checkpoint inhibitor. The commonest cancers were lung (20%), followed by gastric (17%) and metastatic melanoma (16%). The indication for JAK inhibitor therapy for irAEs was predominantly myocarditis (70%), followed by myositis (33%) and hepatitis (24%). Tumour progression was observed in 38% of patients, with 14% remaining in remission. Across all patients, 4% died due to progression of their cancer. CONCLUSION: JAK inhibitors are emerging as a promising option for the treatment of immune checkpoint inhibitor-related toxicities. The currently published evidence, primarily from case reports and case series, suggests they have efficacy, particularly in patients who have failed to respond to other cytokine inhibition strategies.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Nagra D, Song K, Odia J, et al. The therapeutic potential for JAK inhibitors for immune-related adverse events from checkpoint inhibitors: a review of the literature. Rheumatology (Oxford). 2025. PMID: 40587102. doi:10.1093/rheumatology/keaf356

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。